Mavorixafor: Revision history

Filter revisionsshowhide

To date:

Tag filter:

Invert selection

External tools:

For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

curprev 13:5213:52, 10 May 2024‎ Marbletan talk contribs‎ 9,573 bytes −18‎ no longer a stub undo

curprev 10:1310:13, 1 May 2024‎ Mfernflower talk contribs‎ 9,559 bytes −51‎ No edit summary undo Tags: Mobile edit Mobile web edit Advanced mobile edit

curprev 14:4414:44, 30 April 2024‎ Mfernflower talk contribs‎ 9,610 bytes −1,687‎ →‎Research: Already fda approved for WHIM syndrome undo Tags: Mobile edit Mobile web edit Advanced mobile edit
curprev 12:2212:22, 30 April 2024‎ Mfernflower talk contribs‎ 11,297 bytes +14‎ →‎Adverse effects undo Tags: Mobile edit Mobile web edit Advanced mobile edit
curprev 03:1403:14, 30 April 2024‎ Whywhenwhohow talk contribs‎ 11,283 bytes +429‎ add ref undo
curprev 02:3602:36, 30 April 2024‎ Whywhenwhohow talk contribs‎ 10,854 bytes +802‎ Rescuing 3 sources and tagging 0 as dead.) #IABot (v2.0.9.5 undo Tag: IABotManagementConsole [1.3]

curprev 22:3022:30, 29 April 2024‎ Whywhenwhohow talk contribs‎ 10,052 bytes +18‎ add template undo
curprev 22:2822:28, 29 April 2024‎ Whywhenwhohow talk contribs‎ 10,034 bytes +3,944‎ update infobox, description, uses, cats; add US; move text undo

curprev 09:0209:02, 6 January 2024‎ OAbot talk contribs‎ m 6,084 bytes +14‎ Open access bot: pmc updated in citation with #oabot. undo

curprev 14:5414:54, 3 December 2023‎ OAbot talk contribs‎ m 3,381 bytes +34‎ Open access bot: doi updated in citation with #oabot. undo

curprev 19:5019:50, 30 November 2023‎ Buidhe talk contribs‎ 3,347 bytes +33‎ added Category:Experimental drugs using HotCat undo
curprev 19:5019:50, 30 November 2023‎ Buidhe talk contribs‎ 3,314 bytes +3,314‎ ←Created page with ''''Mavorixafor''' (X4P-001)<ref>{{cite journal |last1=Liu |first1=Weiyuan |last2=Bi |first2=Siju |last3=Tian |first3=Ting |last4=Zhou |first4=Ting |last5=Lin |first5=Kuaile |last6=Zhou |first6=Weicheng |title=A Novel and Practical Synthesis of Mavorixafor |journal=Organic Process Research & Development |date=17 June 2022 |volume=26 |issue=6 |pages=1831–1836 |doi=10.1021/acs.oprd.2c00076}}</ref> is an orally bioavailable CXCR4 antagonist.<ref name=Mela...'